Show simple item record

dc.contributor.authorFelici, Emiliano
dc.contributor.authorGonzález Martínez, Coral 
dc.contributor.authorValero Griñán, María Teresa 
dc.contributor.authorGato-Zambrano, Sheila
dc.contributor.authorPereira, Sirley
dc.contributor.authorFernández-Baldo, Martín-A.
dc.contributor.authorOrtega Sánchez, Francisco Gabriel
dc.date.accessioned2025-04-28T06:33:43Z
dc.date.available2025-04-28T06:33:43Z
dc.date.issued2025
dc.identifier.citationPublished version: Felici, Emiliano et al. Talanta Volume 293, 1 October 2025, 128130. https://doi.org/10.1016/j.talanta.2025.128130es_ES
dc.identifier.urihttps://hdl.handle.net/10481/103813
dc.descriptionUniversidad Nacional de San Luis (PROICO 02–2220), Agencia Nacional de Promoción Científica y Tecnológica (PICT-2021-GRF-TI-00136). Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) (PIP–11220200100033CO). Instituto de Salud Carlos III (ISCIII) (PI22_01275, CP23/00134, DTS23_00030). Universidad de Granada (P32/22/02).es_ES
dc.description.abstractProstate cancer (PCa) is the second most commonly diagnosed cancer in men worldwide, and its early detection is critical for improving patient outcomes through timely and effective treatment. In this work, we present the first electrochemical immunoplatform based on magnetic microbeads (MBs) for the determination of epithelial extracellular vesicles (EpEVs), which are emerging as promising biomarkers for PCa diagnosis and prognosis. The immunoplatform employs MBs functionalized with anti-EpCAM antibodies to selectively capture EpEVs, forming sandwich-type immune complexes that are detected via amperometry at disposable screen-printed carbon electrodes. The method demonstrated a detection limit of 0.4 ng µL⁻¹ of EpEVs obtained from PC-3 cell line´s culture, excellent reproducibility (coefficient of variation < 5%), and high selectivity against potential interferences. Comparative analysis with colorimetric immune-magnet ELISA test showed a strong correlation between the two methods, confirming the reliability of the proposed approach. Furthermore, the electrochemical platform provided better precision and a lower limit of detection than the immune magnet ELISA method, indicating its superior analytical performance. Clinical validation using patient samples revealed that the combination of EpEV detection with PSA levels significantly improves the sensitivity and specificity of PCa diagnosis. This novel immunoplatform represents a promising analytical tool for early detection and monitoring of PCa, with potential applications in personalized cancer management.es_ES
dc.description.sponsorshipUniversidad Nacional de San Luis (PROICO 02–2220)es_ES
dc.description.sponsorshipAgencia Nacional de Promoción Científica y Tecnológica (PICT-2021-GRF-TI-00136)es_ES
dc.description.sponsorshipConsejo Nacional de Investigaciones Científicas y Técnicas (CONICET) (PIP–11220200100033CO)es_ES
dc.description.sponsorshipInstituto de Salud Carlos III (ISCIII) (PI22_01275, CP23/00134, DTS23_00030)es_ES
dc.description.sponsorshipUniversidad de Granada (P32/22/02)es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.titleElectrochemical immunoplatform for the quantification of epithelial extracellular vesicles applied to prostate cancer diagnosises_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1016/j.talanta.2025.128130
dc.type.hasVersionSMURes_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record